Duality Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Duality Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-34,196	Closed	-$2.12M	–	821
2022 Q3	$2.12M	Sell	34,196 -2,716	-7%	-$190K	0.23%	170
2022 Q2	$2.94M	Buy	+36,912	New	+$3.5M	0.29%	114
2021 Q3	–	Sell	-6,687	Closed	-$626K	–	753
2021 Q2	$626K	Buy	+6,687	New	+$615K	0.06%	409
2021 Q1	–	Sell	-30,826	Closed	-$2.25M	–	752
2020 Q4	$2.25M	Buy	+30,826	New	+$2.29M	0.17%	185

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Duality Advisers's HZNP Position: Q4 2022 in Review

Duality Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 34,196 shares — an estimated $2.12M sold.

Duality Advisers first reported a position in HZNP in Q4 2020 and held it in 4 quarters. The position peaked at $2.94M in Q2 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Duality Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Duality Advisers sold 34,196 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $2.12M.
Duality Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 4 quarters.
Duality Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.94M in Q2 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Duality Advisers's 13F filing for Q4 2022, filed 7 Feb 2023.